[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-risk-of-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-risk-of-stroke":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100623427","a-prospective-single-arm-study-evaluating-the-endothelialization-effect-and-timeline-of-anchorman-left-atrial-appendage-occluder-in-non-valvular-atrial-fibrillation-patients-at-high-risk-of-stroke-100623427",false,"NCT07396493","A Prospective, Single-arm Study Evaluating the Endothelialization Effect and Timeline of AnchorMan® Left Atrial Appendage Occluder in Non-valvular Atrial Fibrillation Patients at High Risk of Stroke","AnchorMan-NVAF","Inclusion Criteria:\n\n1. Age ≥ 18 years with non-valvular atrial fibrillation (NVAF).\n2. High stroke risk: CHA2DS2-VASc score ≥ 2 (Male) or ≥ 3 (Female) AND meeting any of the following:\n\n   1. Documented history of bleeding (\\> 6 months ago) or bleeding tendency (e.g., gingival, nasal, GI, urinary tract, cerebral hemorrhage).\n   2. Intolerance or unwillingness to undergo long-term anticoagulation therapy.\n   3. Recurrent stroke or embolic events despite standardized anticoagulation.\n   4. Predicted high bleeding risk (HAS-BLED score ≥ 3).\n   5. Status post-Left Atrial Appendage Electrical Isolation (LAAEI).\n3. Subject or legal representative understands the study purpose, is willing to cooperate with surgery and follow-up, and has signed the written Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n1. Rheumatic heart disease, moderate-to-severe mitral stenosis\u002Fregurgitation, severe aortic valve disease, or severe LVOT obstruction (gradient \\> 40 mmHg).\n2. Left ventricular ejection fraction (LVEF) \\\u003C 30%.\n3. Complex LAA anatomy unsuitable for LAAO implantation.\n4. Pericardial effusion \\> 10mm.\n5. Planned ablation or cardioversion post-procedure.\n6. Intracardiac thrombus (including left\u002Fright atrium).\n7. Myocardial infarction within the last 3 months.\n8. History of ASD repair or PFO occluder implantation.\n9. History of heart valve replacement (mechanical valve).\n10. Heart transplant recipient.\n11. New-onset ischemic stroke or TIA within the last 30 days.\n12. Severe heart failure (NYHA Class IV).\n13. Severe renal impairment: eGFR \\\u003C 45 ml\u002Fmin\u002F1.73m² or on dialysis.\n14. Hypersensitivity or contraindication to aspirin, clopidogrel, heparin, contrast media, or nitinol.\n15. Pregnant or lactating women, or those planning pregnancy within one year.\n16. Life expectancy \\\u003C 12 months.\n17. Unable to complete 2 months of anticoagulation or 6 months of DAPT for any reason.\n18. Investigator's judgment of poor compliance or inability to complete the study requirements.","ALL","18 Days",{"count":19,"type":20},306,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the endotheliation efficacy of the AnchorMane® Left Atrial Appendage Occluder in non-valvular atrial fibrillation patients at high stroke risk. It investigates the rate of complete endotheliation of the occluder at 6 months post-procedure using routine cardiac CTA, providing additional data for clinical application and further product development.\n\nStudy Size and Duration: This study plans to enrol1 306 patients. All participants will undergo follow up immediately after occluder implantation, prior to discharge or within 7 days post-procedure, at 1 month post-procedure, at 3 months post-procedure,and at 6 months post-procedure. The total study duration is projected to be 3 year.\n\nThe expected duration of participation for each participant is approximately 6 months.",[26,27],"Non-valvular Atrial Fibrillation (NVAF)","High Risk of Stroke",[29,30,31],"Non-valvular atrial fibrillation (NVAF)","high risk of stroke.","Left Atrial Appendage Occluder System","NOT_YET_RECRUITING","2026-02-02",{"date":35,"type":36},"2026-02-09","ACTUAL",{"date":38,"type":20},"2026-02-08",{"date":40,"type":20},"2027-12-31",{"name":42,"class":43},"Shanghai Zhongshan Hospital","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100523633","oriental-intervention-for-enhanced-neurocognitive-health-orient-diet-in-populations-with-high-risk-of-stroke-ends-100523633","NCT06098235","Oriental Intervention for Enhanced Neurocognitive Health (Orient) Diet in Populations With High Risk of Stroke (ENDS)","Oriental Intervention for Enhanced Neurocognitive Health (Orient) Diet in Populations With High Risk of Stroke (ENDS): a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged ≥ 40 years\n* High risk of stroke (with ≥ 3 of 8 stroke risk factors, including hypertension, dyslipidemia, diabetes, atrial fibrillation or valvular heart disease, smoking history, obvious overweight or obesity, lack of exercise, family history of stroke, or with transient ischemic attack)\n* Written informed consent available\n* Willingness to complete all assessments and participate in follow-up\n* Adequate Visual and auditory acuity to undergo neuropsychological testing\n\nExclusion Criteria:\n\n* Nuts, berries, olive oil, or fish allergies\n* previously diagnosed dementia\n* Suspected dementia after clinical assessment by study physician at screening visit\n* Previous history of major head trauma and any intracranial surgery\n* Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions\n* Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement\n* Severe loss of vision, hearing, or communicative ability\n* Patients presenting a malignant disease with life expectancy \\\u003C 3 years\n* Participation in an ongoing investigational drug study\n* Any MRI contraindications\n\nExit Criteria:\n\n* Not meet the inclusion criteria\n* For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator\n* Any adverse or serious adverse events during the study period judged by Investigator","40 Years",{"count":53,"type":20},160,[23],"This randomized controlled trial will enroll 160 individuals aged over 40 without dementia who are at high risk of stroke, collecting multi-modal MRI imaging, serum, and fecal samples to investigate the impact of the ORIENT diet on brain functional networks.",[27],[58,59],"stroke","Brain functional network connectivity","RECRUITING","2025-06-11",{"date":63,"type":36},"2025-06-15",{"date":65,"type":36},"2023-11-01",{"date":67,"type":20},"2026-06-30",{"name":69,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University",1]